Omnicare, Inc. says that it will continue to pursue an appeal vigorously and seek reversal of the summary judgment on the antitrust and fraud action entitled Omnicare, Inc. v. UnitedHealth Group, Inc., et al., 2:06-cv-00103-WOB.
On May 18, 2006, the action…
Omnicare, Inc. says that the Company has until September 29, 2009, to answer or respond to the qui tam complaint filed by Bernard Lisitza alleging violations of the False Claims Act.
On October 30 and 31, 2008, Omnicare was provided with…
Omnicare, Inc. says that the Company has until September 29, 2009, to answer or respond to the qui tam complaint filed by Deborah Maguire alleging violations of the False Claims Act.
On October 27, 2008, the U.S. District Court in Boston,…
Omnicare, Inc. says that on or about June 24, 2009, the Company reached an agreement in principle, without admitting liability, with the U.S. Attorney s Office, District of Massachusetts, pursuant to which it would pay US$98 million plus interest from…
Covidien Ltd. disclosed in its latest quarterly report on Form 10- Q filed with the U.S. Securities and Exchange Commission an appeal over US$8.7 million for attorney’s fees and costs in Masimo Corporation’s favor is still ongoing.
Masimo Corporation v. Tyco…
Mallinckrodt Inc., a subsidiary of Covidien Ltd., is one of four manufacturers of gadolinium-based contrast agents still involved in litigation alleging that administration of these agents causes development of a recently-identified disease, nephrogenic systemic fibrosis, in a small number of…
Omnicare, Inc. says that the Company has until September 29, 2009, to answer or respond to the qui tam complaint filed by David Kammerer alleging violations of the False Claims Act.
On October 30 and 31, 2008, Omnicare was provided with…
Biogen Idec Inc. disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission that it anticipates the trial on the Massachusetts Department of Revenue’s US$38.9 million tax assessment against its wholly owned subsidiary,…
Biogen Idec Inc. disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission that the European Commission, or the EC, published its final report on an inquiry in July 2009 in which it…
Biogen Idec Inc. disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission that on June 15, 2009, a panel issued its final decision in the arbitration filed by the Company against Genentech,Inc.…